Comparison
18q Partial Monosomy Syndrome C0265472 vs 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Clinical comparison between 18q Partial Monosomy Syndrome and 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 for differential diagnosis and treatment planning.
18q Partial Monosomy Syndrome C0265472
A chromosomal disorder involving deletion of part of chromosome 18. Causes developmental delays, intellectual disability, and various physical features. Treatment focuses on managing specific symptoms.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
6 comparison axes
Onset
18q Partial Monosomy Syndrome C0265472
0-0
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
Onset patterns differ
Severity
18q Partial Monosomy Syndrome C0265472
severe
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
Different severity levels
Chronic
18q Partial Monosomy Syndrome C0265472
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
Differing course
Communicable
18q Partial Monosomy Syndrome C0265472
No
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
Different transmission
Body System
18q Partial Monosomy Syndrome C0265472
congenital
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Same/different system
Category
18q Partial Monosomy Syndrome C0265472
genetic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Different category
Bottom line
18q-partial-monosomy-syndrome-C0265472 and 17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 18q Partial Monosomy Syndrome C0265472 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Discriminating power |
|---|---|---|---|
| Development | Developmental delay and intellectual disability are central from early life. | Cognition is not the defining problem in the supplied description. | High |
| Puberty and blood pressure | Not primarily defined by absent puberty or hormone-related hypertension. | Ambiguous genitalia, lack of puberty, and high blood pressure are described. | High |
| Cause | Partial deletion of chromosome 18. | Impaired steroid hormone production from an enzyme deficiency. | High |
When to favor each condition
Choose 18q Partial Monosomy Syndrome C0265472 when
Congenital developmental delay with variable physical features
This pattern fits a chromosomal disorder better than an isolated enzyme defect.
Moderate
Confirmed partial deletion of chromosome 18q
Direct chromosomal evidence supports 18q partial monosomy.
High
No clinical steroid-synthesis pattern
Absence of the described endocrine picture makes the enzyme deficiency less likely.
Moderate
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with delayed or absent puberty
This combination suggests disordered adrenal and sex-steroid production.
Moderate
Ambiguous genitalia plus compatible hormone findings
The clinical and biochemical pattern points toward the enzyme deficiency.
High
Normal chromosomal study with relevant gene confirmation
A gene-level diagnosis distinguishes it from an 18q deletion.
High
How key tests differ
| Test | 18q Partial Monosomy Syndrome C0265472 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Interpretation |
|---|---|---|---|
| Karyotype or chromosomal microarray | Partial deletion involving 18q. | No 18q deletion expected; routine karyotype may be normal. | A confirmed deletion supports the chromosomal condition but does not diagnose the enzyme disorder. |
| Blood pressure and electrolytes | No specific mineralocorticoid pattern is established here. | Hypertension and low potassium are often evaluated; no cutoff is supplied. | Abnormal results require clinician correlation and do not alone prove either diagnosis. |
| Steroid profile and genetic testing | A primary 17-hydroxylase/lyase block is not expected. | Impaired cortisol and sex-steroid production may be found; gene testing can confirm. | Use laboratory reference ranges. This comparison provides no numeric cutoffs. |
Prognosis comparison
18q Partial Monosomy Syndrome C0265472
- Outcome
- Chronic condition with variable developmental and medical needs; survival figures are not established here.
- Factors
- Deletion extent, associated anomalies, available support, and comorbidities.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine condition; puberty and blood-pressure outcomes depend on recognition and treatment.
- Factors
- Enzyme deficiency severity, blood-pressure control, hormone therapy, and genital differences.
Time frame: Lifelong. Onset is congenital for 18q deletion and from birth through adolescence for the enzyme disorder.
Early diagnosis and individualized specialist care influence function, but comparative prognosis is not firmly established.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopment | Delay and intellectual disability may require lasting support. Neurodevelopment is not identified as the defining complication. Severity varies, and a uniform outcome should not be assumed. |
| Sexual development | Not primarily defined by ambiguous genitalia or absent puberty. Ambiguous genitalia and lack of puberty may occur. Hormone replacement is lifelong when indicated, with specialist-selected doses. |
| Blood pressure effects | No specific hypertension mechanism is established by these data. High blood pressure may threaten organs if inadequately managed. Monitoring is clinical; no mortality estimate is established here. |
Patient education highlights
- HighDifferent causes
One is a chromosome 18 deletion; the other affects steroid production. Neither is contagious.
- HighSpecialist testing
Genetics and, for the enzyme disorder, hormone tests guide diagnosis. Results need clinician interpretation.
- MediumCare focus
18q care manages individual symptoms; the enzyme disorder needs lifelong hormone therapy. Do not use unverified doses.